[go: up one dir, main page]

WO2008028065A3 - Sirt activation in managing heart failure - Google Patents

Sirt activation in managing heart failure Download PDF

Info

Publication number
WO2008028065A3
WO2008028065A3 PCT/US2007/077280 US2007077280W WO2008028065A3 WO 2008028065 A3 WO2008028065 A3 WO 2008028065A3 US 2007077280 W US2007077280 W US 2007077280W WO 2008028065 A3 WO2008028065 A3 WO 2008028065A3
Authority
WO
WIPO (PCT)
Prior art keywords
activation
heart failure
sirt1
sirt3
hypertrophy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/077280
Other languages
French (fr)
Other versions
WO2008028065A2 (en
Inventor
Mahesh Gupta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of WO2008028065A2 publication Critical patent/WO2008028065A2/en
Publication of WO2008028065A3 publication Critical patent/WO2008028065A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01098—Histone deacetylase (3.5.1.98), i.e. sirtuin deacetylase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Activation of a member of a class III histone deacetylase (e.g., SIRT1 and SIRT3) inhibits or blocks most of the events associated with heart failure (e.g., cardiomyocyte hypertrophy, cell death, loss of α-myosin isoform shift and fetal gene activation) and protects myocytes from hypertrophy agonist-mediated cell-death. SIRT1 and SIRT3 activation favors α-MHC expression and alters the myosin-isoform switch from β-MHC to α-MHC during cardiac hypertrophy. SIRT1 and SIRT3 activation negatively regulates cardiac hypertrophy and cell-phenotype, and these characteristics of SIRTs are therapeutically valuable for the treatment of heart failure.
PCT/US2007/077280 2006-08-31 2007-08-30 Sirt activation in managing heart failure Ceased WO2008028065A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82410106P 2006-08-31 2006-08-31
US60/824,101 2006-08-31

Publications (2)

Publication Number Publication Date
WO2008028065A2 WO2008028065A2 (en) 2008-03-06
WO2008028065A3 true WO2008028065A3 (en) 2008-12-18

Family

ID=39136902

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/077280 Ceased WO2008028065A2 (en) 2006-08-31 2007-08-30 Sirt activation in managing heart failure

Country Status (1)

Country Link
WO (1) WO2008028065A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2214698A2 (en) * 2007-10-23 2010-08-11 President and Fellows of Harvard College Use of compounds activating sirt-3 for mimicking exercise
US20120283269A1 (en) * 2009-11-04 2012-11-08 Health Research Inc. Method and Compositions for Suppression of Aging
CN116808217A (en) * 2023-06-06 2023-09-29 中国医科大学附属第一医院 Application of MHC lactate regulating preparation in preparation of medicine for promoting relevant diseases of organism lactate level

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHENG ET AL.: "Inhibitory effect of resveratrol on angiotensin Il-induced cardiomyocyte hypertrophy", NAUNYN-SCHMIEDEBERG'S ARCH. PHARMACOL., vol. 369, 2004, pages 239 - 244 *
KOBAYASHI ET AL.: "SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress", INT. J. MOL. MED., vol. 16, 2005, pages 237 - 243 *

Also Published As

Publication number Publication date
WO2008028065A2 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
WO2007146706A3 (en) Modified dicamba monooxygenase enzyme and methods of its use
WO2005114190A3 (en) Methods of identifying biomarkers
WO2008060622A3 (en) Improved methods and compositions for wound healing
EP2535050A3 (en) Compositions and methods for detection of lysosomal storage disease
NL300874I2 (en) Elosulfase alpha
WO2008082730A3 (en) Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
WO2007101225A3 (en) Methods to identify inhibitors of the unfolded protein response
FI20050011L (en) Method and test kit for detecting the risk of type 2 diabetes mellitus
DK1848718T3 (en) E1 activation enzyme inhibitors
EP2620150A3 (en) 2-amido thiazole based inhibitors of ATP-utilizing enyzmes
NO345139B1 (en) Florizine analogues as inhibitors of glucose ecotransporter 2 and their pharmaceutical composition
WO2011019393A3 (en) Class- and isoform-specific hdac inhibitors and uses thereof
WO2008047150A3 (en) Protein variants
WO2009152484A3 (en) Methods and platforms for drug discovery
WO2008027428A3 (en) Gene expression profiling for identification, monitoring and treatment of transplant rejection
EP2068913A4 (en) IMMUNOMODULATORS, PREPARATIONS AND COMPOSITIONS COMPRISING THESE IMMUNOMODULATORS, TESTS FOR ASSESSING THE ACTIVITY OF THESE IMMUNOMODULATORS AND PREPARATIONS AND COMPOSITIONS COMPRISING SAME, AND ASSOCIATED METHODS
IL195498A0 (en) Active agent combinations with insecticidal and acaricidal properties
WO2009023773A8 (en) Galactokinase inhibitors
WO2009158031A3 (en) Methods and compositions for therapeutic treatment
WO2007031965A3 (en) Lotioned fibrous structures
EP2343370B8 (en) A thrombin-like enzyme of agkistrodon acutus
WO2008028065A3 (en) Sirt activation in managing heart failure
IL195815A0 (en) Active agent combinations with insecticidal and acaricidal properties
IL201170A0 (en) Measurement of the activity of a kynurenine-converting enzyme and/or of a kynurenic acid, anthranilic acid and/or 3-hydoxykynurenine-producing enzyme
WO2008070552A3 (en) Inhibitors of protein tyrosine phosphatase for the promotion of physiological cardiac hypertrophy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07841645

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07841645

Country of ref document: EP

Kind code of ref document: A2